Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Identifieur interne : 009196 ( Ncbi/Curation ); précédent : 009195; suivant : 009197Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Auteurs : Tessa G. Steenbruggen [Pays-Bas] ; Mette S. Van Ramshorst [Pays-Bas] ; Marleen Kok [Pays-Bas] ; Sabine C. Linn [Pays-Bas] ; Carolien H. Smorenburg [Pays-Bas] ; Gabe S. Sonke [Pays-Bas]Source :
- Drugs [ 1179-1950 ] ; 2017.
Abstract
In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.
DOI: 10.1007/s40265-017-0774-5
PubMed: 28616845
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000145
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000145
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000145
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :009196
Links to Exploration step
pubmed:28616845Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</title>
<author><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28616845</idno>
<idno type="pmid">28616845</idno>
<idno type="doi">10.1007/s40265-017-0774-5</idno>
<idno type="wicri:Area/PubMed/Corpus">000145</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000145</idno>
<idno type="wicri:Area/PubMed/Curation">000145</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000145</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000145</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000145</idno>
<idno type="wicri:Area/Ncbi/Merge">009196</idno>
<idno type="wicri:Area/Ncbi/Curation">009196</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</title>
<author><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Drugs</title>
<idno type="eISSN">1179-1950</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009196 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 009196 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:28616845 |texte= Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:28616845" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |